XNYS · Healthcare · Medical Devices
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-16 | Q1 2026 | 1.14 | 1.15 | +0.88% | $11.16B | ✅ Beat | +0.49% | -3.13% | -11.52% |
| 2026-01-22 | Q4 2025 | 1.50 | 1.50 | +0.00% | $11.46B | ➖ Inline | +0.10% | -2.32% | +3.31% |
| 2025-10-15 |
| Q3 2025 |
| 1.30 |
| 1.30 |
| +0.00% |
| $11.37B |
| ➖ Inline |
| — |
| — |
| — |
| 2025-07-17 | Q2 2025 | 1.25 | 1.26 | +0.80% | $11.14B | ✅ Beat | — | — | — |
| 2025-04-16 | Q1 2025 | 1.07 | 1.09 | +1.87% | $10.36B | ✅ Beat | — | — | — |
| 2025-01-22 | Q4 2024 | 1.34 | 1.34 | +0.00% | $10.97B | ➖ Inline | — | — | — |
| 2024-10-16 | Q3 2024 | 1.20 | 1.21 | +0.83% | $10.63B | ✅ Beat | — | — | — |
| 2024-07-18 | Q2 2024 | 1.10 | 1.14 | +3.64% | $10.38B | ✅ Beat | — | — | — |
Showing last 8 quarters.